Merck KGaA is in the investment-grade market Tuesday, a day after holding investor calls, to help fund its $3.9 billion ...

Immunome's varegacestat shows promising efficacy in desmoid tumors, with phase 3 topline data expected by 2025-end. Read why ...

Shares of SpringWorks Therapeutics SWTX have rallied 32.9% in the past three months compared with the industry’s increase of 2.7%. Here, we discuss the reasons for the same. Strong Launch of ...

SpringWorks Therapeutics’ SWTX oral gamma-secretase inhibitor, Ogsiveo (nirogacestat), was approved by the FDA for treating adult patients with progressing desmoid tumors in November 2023.

Shares of SpringWorks Therapeutics, Inc. SWTX have rallied 81% in the past three months compared with the industry’s increase of 15.9%. In November 2023, the FDA approved SpringWorks’ oral ...

SpringWorks' (SWTX) Ogsiveo is the first drug approved by the FDA to treat desmoid tumors. The company's efforts to develop its pipeline candidate, mirdametinib, for treating NF1-PN also hold promise.

SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for patients living with ...

SpringWorks is using Nirogacestat, while AbbVie provides ABBV-383. It is believed that Nirogacestat provides a boost for BCMA therapies like ABBV-383. This isn't the first partnership for SpringWorks.

SpringWorks is a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and delivering life-changing medicines for people with severe rare diseases and cancer.

SpringWorks is committed to improving our understanding of desmoid tumors. There’s a significant need for more education and we are working with urgency and tenacity to help improve the outcomes for ...

SpringWorks launched last year with $103 million in financing, led by Bain Capital, OrbiMed Advisors and Pfizer Inc., and a plan to develop treatments for patients who lack good treatment options.